Product Overview

Kanjinti 150 mg Powder for concentrate for solution for infusion is a targeted biological therapy manufactured by Amgen. It is a biosimilar to trastuzumab, an established treatment for certain types of cancer. Kanjinti is specifically indicated for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

As referenced on leading pharmaceutical platforms like Nahdi Online and medical e-commerce sites, this medication works by targeting and blocking the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in certain aggressive cancers, thereby inhibiting the growth and spread of cancer cells.

Key Benefits

Kanjinti offers several significant benefits for eligible patients:

• Targets HER2-positive cancer cells specifically, minimizing impact on healthy cells.
• Improves progression-free survival and overall survival in HER2-positive breast cancer and gastric cancer patients.
• Can be used as monotherapy or in combination with chemotherapy, depending on the treatment regimen.
• Provides a biosimilar option, expanding access to effective trastuzumab therapy.

How to Use

Kanjinti 150 mg is for intravenous administration only and must be prepared and administered by a healthcare professional.

1. The powder in the vial is reconstituted with sterile water for injection to create a concentrate.
2. The reconstituted solution is then further diluted in an infusion bag containing 0.9% sodium chloride injection.
3. Administer the diluted solution via intravenous infusion over a specified period, typically 30 to 90 minutes, as prescribed by the treating physician.
4. Dosage and frequency of administration are determined by the physician based on the patient's body weight, specific cancer type, and overall treatment plan.
5. Patients should be monitored closely during and after infusion for any adverse reactions.

Caution & Warnings

• Cardiotoxicity: Kanjinti can cause left ventricular dysfunction and congestive heart failure. Cardiac function should be assessed before and during treatment.
• Infusion-Related Reactions: Severe reactions, including anaphylaxis, can occur. Patients should be monitored during infusion and resuscitation equipment should be available.
• Pulmonary Toxicity: Rarely, severe pulmonary events, including interstitial pneumonitis, have been reported.
• Embryo-fetal Toxicity: Kanjinti can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during and for 7 months following treatment.
• Neutropenia: Decreased white blood cell count can occur, increasing infection risk.
• This medication must be prescribed and administered under the supervision of a qualified physician experienced in oncology and the use of targeted therapies.

Ingredients

• Active Ingredient: Trastuzumab (150 mg per vial)
• Excipients: L-Histidine, L-Histidine hydrochloride monohydrate, alpha,alpha-Trehalose dihydrate, Polysorbate 20.

Product Details

• Form: Powder for concentrate for solution for infusion
• Strength: 150 mg
• Package Type: Vial
• Storage: Store in a refrigerator (2°C - 8°C). Do not freeze. Protect from light.
• Manufacturer: Amgen